Low Float (SILO) Jumps The Opening Bell With Green Surge (Holds Strong Above 2 Key Support Lines)

SILO is popping-off early this morning and requires full focus. Low Float (SILO) Jumps The Opening Bell With Green Surge (Holds Strong Above 2 Key Support Lines) August 2nd Dear Reader, SILO is popping-off early this morning and requires full focus. Right now, SILO is trading above [two of the most important lines]( of potential support in its 50-Day Simple Moving Average (SMA) and its 13-Day Exponential Moving Average (EMA). But here's the thing to take a close look at... The last 3 days SILO has closed above both of those lines suggesting support could be building at those key levels. And with a 200-Day SMA dropping daily, it may just be a matter of time until SILO turns into a squeeze situation. With SILO trading at levels it hasn't seen in over a month plus, it could be the ultimate time to get this Nasdaq idea on radar. Don't forget, SILO is a [low float profile]( (fewer than 3Mn shares), which means volatility needs to be on full notice at all times. Take a moment right now to reread my initial report below and get SILO on your watch-list before it's too late. ----- Hot off Tuesday's breakout idea which resulted in a high providing an approximate 31.6% surge from the previous day's close, I want to draw your attention to another Nasdaq profile. Here's why... A recent study conducted by Harvard revealed some rather disconcerting information. (1) It is projected that the healthcare expenses associated with mental health conditions will surge to $6Tn by 2030. Considering the content of global news on a daily basis, mental health is undeniably a subject to closely monitor in the forthcoming years. One particular market that has shown substantial growth and gained attention in treating such conditions and other illnesses is the therapeutic market involving psych-e-delics. According to Data Bridge Market Research, this market is expanding at a rate that could reach $8Bn by 2029. (2) In essence, there are ample opportunities available for companies to step in and make a difference. Right now, I wish to draw your attention to one specific company that seems to be well-positioned to establish a notable presence in these burgeoning markets. And based on its tiny float, two recently awarded patents, two new research agreements, and "positive results" from a key toxicology study, this profile needs top spot on your watch-list Wednesday: Silo Pharma, Inc. (SILO) Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. And based on these potential catalysts, SILO needs to be put on breakout watch. Check them out: No. 1 - Low Float Volatility Could Pop Up On Daily Basis No. 2 - Two Awarded Patents Aim To Protect IP's Key Technology No. 3 - Company Enters Into Game-Changing Agreement To Develop Implant For Fibromyalgia Treatment No. 4 - Study's Phase 2 Will Help To Further Investigate Cyclic Peptides In Human Tissue No. 5 - "Positive Results" Provide A Spotlight On SP-26 (Continuing Progression To Human Trials) But more on those in a second... The Silo Difference The company is committed to developing innovative solutions to address a variety of underserved conditions including Alzheimer’s; Parkinson’s; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders. While partnering with some of the leading Academic Institutions, Silo has licensed therapeutics that will allow the company to pursue the more streamlined 505(b)(2) route for trials. Silo anticipates this strategy will lower cost and allow for a faster approval process to help patients with few if any proven addressable therapeutics. Pipeline - Showing Promise In A Range Of Illnesses And Diseases SPC-14 - Targeting Alzheimer’s Regulatory Pathway & Results - 505(b)(2) Pathway - Preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University - SPC-14 has shown reduced hyponeophagia in animal studies - SPC-14 may reduce behavioral despair - Silo has licensed technology with Columbia and has recently entered into a scientific research agreement with Dr. Denny’s lab Market Opportunity - Alzheimer’s Disease - 6.5 million Americans suffer from Alzheimer’s and related diseases - ~1 in 9 Americans 65+ have Alzheimer’s - U.S. market for relevant drugs expected to reach $5Bn by 2027 ----- SPC-15 - Targeted prophylactic treatment—Stress-induced affective disorders Applications - Sponsored Research Agreement with Columbia University Prevention of stress-induced affective disorders - Increasing stress resilience in military, first responders, and other populations at high risk of PTSD - Predicting the level of severity or progression such disorders - Molecular targets for use in drug discovery of innovative treatments Market Opportunity - 26% of Americans 18+ suffer from anxiety, PTSD and other disorders - This number has escalated post-CV-19 - U.S. market for relevant drugs expected to reach $13Bn by 2027 ----- SP-26 - Time-Released Psi-lo-cybin, Keta-mine Applications - Deliver Keta-mine or Psi-lo-cybin in a time-released manner - Will time-release diminish the hallucinogenic effects of these psych-e-delics - Pre clinical study underway shows Z-pod can hold and distribute Keta-mine - Efficacy study in animals underway ----- SPU-16 - CNS Homing Peptide Regulatory Pathway & Results 505(b)(2) Pathway - May be used as a delivery tool to target current therapies to detect inflammation in the spinal cord - May be used for diagnosing and monitoring MS - Decreases toxicity of existing therapeutics - Animal study results show much improved delivery of therapeutics and decreased toxicity. Market Opportunity - There are approximately 400,000 Americans and 2.5 million people worldwide with MS - The most widespread disabling neurological condition of young adults - Global market for MS drugs expected to reach $25.3Bn by 2027 ----- SPU-21 - Arthritogenic Joint Homing Peptides Utilizing Psi-lo-cybin Applications - Identify markers of arthritic inflammation in joints - Isolate phage clones that preferentially target inflamed joints of arthritic Lewis rats - Peptide significantly inhibited arthritic progression in this animal model - Further studies are underway at UMB Market Opportunity - 1.3Mn U.S. adults suffer from RA - The most common autoimmune disease in U.S. - U.S. market for RA drugs expected to reach $63Bn by 2027 [Grab more key company details/sources here.]( ----- Right now, SILO has several potential catalysts that could provide it with a breakout spark. Here's what to know: No. 1 SILO Potential Catalyst - Low Float Volatility Could Pop Up On Daily Basis According to the [Yahoo Finance website]( SILO has a low float. The website reports this profile to have approximately 2.57Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could more 2023 positive company news help provide a near term spark? ----- No. 2 SILO Potential Catalyst - Two Awarded Patents Aim To Protect IP's Key Technology In the last few months, SILO has been awarded two, game-changing patents further helping to protect their IP. Check them out: #1. [Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent]( Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. The expanded claims in this new patent grant reinforce protection for our ongoing development of SPU-21 guided delivery of targeted psi-lo-cybin as a therapeutic agent for rheumatoid arthritis (RA), our initial indication.” #2. [Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease]( “This patent is an important addition to our intellectual property, further protecting the key technology behind SPC-15 in which metabolomic biomarkers predict the response to pharmacological treatments and measure efficacy,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “Based on our latest research with Columbia University on SPC-15, this IP expands the claims of the original patent.” ----- No. 3 SILO Potential Catalyst - Company Enters Into Game-Changing Agreement To Develop Implant For Fibromyalgia Treatment Silo Pharma Signs Agreement to Develop First-in-Class Keta-mine Implant Therapeutic Initial indications are fibromyalgia and chronic pain ENGLEWOOD CLIFFS, NJ, June 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research, today announced its entry into a research and development agreement to study and develop a dosage and time-release keta-mine implant for the treatment of fibromyalgia. The research project includes analytical testing services and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability. “Alongside our development of SP-26, our novel time-release topical formulation of keta-mine, we are beginning to explore an additional option for treating fibromyalgia using keta-mine-loaded implants,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “The outcome of this research will provide additional information and data for our ongoing studies of keta-mine treatments for fibromyalgia and other chronic pain indications.” ... [Read the full article here.]( ----- No. 4 SILO Potential Catalyst - Study's Phase 2 Will Help To Further Investigate Cyclic Peptides In Human Tissue Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21 Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research, today announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “The initial three-month pilot study of SPU-21 assessed the peptide in healthy human and RA synovial tissue. The next step is to further investigate cyclic peptides in human tissue assays for optimization and binding affinity.” Silo Pharma is advancing the development of SPU-21 liposomal joint homing peptides in collaboration with the University of Maryland, Baltimore (UMB). [Read the full article here.]( ----- No. 5 SILO Potential Catalyst - "Positive Results" Provide A Spotlight On SP-26 (Continuing Progression To Human Trials) Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia ENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of keta-mine. The study results evaluated the feasibility of using a rising dose design or maximum feasibility. In collaboration with Experimur, a Frontage Laboratories company, Silo Pharma tested SP-26 in a toxicology and tolerability study in mini pigs using an ascending (descending) dosing regimen. The study utilized the bioanalytical methods required to perform toxicology studies by the U.S. Food and Drug Administration (FDA) in advance of initiating clinical studies for SP-26. “Today’s positive results are an important step as we move closer to achieving all needed components to plan human trials of SP-26,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “We are advancing our work with our regulatory partners to prepare a Pre-Investigational New Drug (IND) package for SP-26 and intend to pursue the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval.” [Read the full article here.]( ----- SILO Recap - Key Potential Breakout Catalysts To Know Now No. 1 - Low Float Volatility Could Pop Up On Daily Basis No. 2 - Two Awarded Patents Aim To Protect IP's Key Technology No. 3 - Company Enters Into Game-Changing Agreement To Develop Implant For Fibromyalgia Treatment No. 4 - Study's Phase 2 Will Help To Further Investigate Cyclic Peptides In Human Tissue No. 5 - "Positive Results" Provide A Spotlight On SP-26 (Continuing Progression To Human Trials) ----- Coverage is officially initiated on SILO. When time permits, do this: Get SILO on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer [Source 1]( [Source 2]( (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 10/11/22 and ending on 10/13/22 to publicly disseminate information about (SILO) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (SILO). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 8/1/23 and ending on 8/2/23 to publicly disseminate information about (SILO) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (SILO). To date we have been compensated a total of forty-two thousand five hundred USD via bank wire transfer to disseminate information about (SILO). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 08/02/2023 and ending on 08/02/2023 to publicly disseminate information about (SILO:US) via digital communications. We have been paid twenty two thousand five hundred dollars USD. To date we have been paid one hundred two thousand five hundred dollars USD to disseminate information about (SILO:US) via digital communications.  [( Fierce | 401 W. Atlantic Ave, Ste R10 Unit #271, Delray Beach, FL 33444 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net